To further investigate the ability of IMC-F106C to redirect T cells to selectively kill PRAME+/HLA-A*02:01+ tumor cells, we developed an organoid model from either PRAME+ or PRAME– tumors. This evidence concerns the gene HLA-A and neoplasm.